Source Bioscience acquires Cambridge Clinical Laboratories

Source BioScience has completed the acquisition of Cambridge Clinical Laboratories (CCL) for an undisclosed sum.

Source, which is based on Histon’s Vision Park, is a leading provider of genomic services and histopathology diagnostics.

The acquisition of CCL, a Milton-based provider of clinical, personalised healthcare testing services, extends Source’s all-round service. Source’s clinical diagnostics portfolio will leverage the expertise of the CCL team and Source’s new cutting-edge clinical lab facilities on Vision Park, providing streamlined testing services for both preclinical and clinical research.

All staff and assets from CCL will be transferred to the new clinical facilities at the existing Source Genomics site at Vision Park. The facilities will provide a significantly larger laboratory footprint, enabling the company to expand the capacity of existing services and explore new capabilities for future projects.

The site will also increase opportunities for collaboration between the genomics and clinical services teams, providing customers with deeper insights into their data.

Tony Cooke, former CEO and now CSO at Cambridge Clinical Laboratories, said: “Source BioScience is a well-established leader in the biopharmaceutical and broader life science service sector, providing data-rich insights into research projects through its genomics and multiomics services, as well as its range of clinical offerings.

“We welcome the opportunity to join forces with Source, which will allow us to bring together the talent and expertise of both companies, ultimately adding more capacity for customers to access these cutting-edge research services, and bring new therapies to patients, faster.”

Jay LeCoque, chairman and CEO of Source BioScience, said: “We’re extremely pleased to welcome Cambridge Clinical Laboratories into our team here at Source BioScience.

“CCL has a long-standing reputation for its expertise in personalised clinical diagnostic services, and as such, represented the ideal opportunity to complete our service offerings.

“By investing in a new clinical lab facility and bringing in the talented team at CCL, we will open up significant new market opportunities in clinical diagnostics and be able to support our customers through all stages of their programmes.”